AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study - Zacks.com
AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study Zacks.com
AstraZeneca (AZN) announces positive overall survival results from the phase III CASPIAN study evaluating Imfinzi in first-line extensive-stage SCLC.
Comments
Post a Comment